Ex-Pur­due Phar­ma chief Mark Tim­ney, named in dozens of opi­oid law­suits, nabs an­oth­er biotech CEO gig

Fac­ing hun­dreds of law­suits over its role in fu­el­ing the US opi­oid epi­dem­ic, Pur­due Phar­ma is in the midst of full-scale tear­down — but that doesn’t mean its for­mer lead­ers aren’t mak­ing off well. Com­ing off a stint dri­ving RNAi ther­a­py in­clisir­an to a buy­out, for­mer Pur­due CEO Mark Tim­ney has found a new home at the helm of a small biotech.

On Mon­day, At­tralus Ther­a­peu­tics an­nounced Tim­ney’s hire as CEO amid a flur­ry of ad­di­tions to the biotech’s brain trust.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER